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A B S T R A C T
Purpose: Most studies of quality of life (QOL) in seizure-free epilepsy patients suggest normal or near-
normal function. Previous studies on QOL in well-controlled epilepsy have not investigated
determinants for QOL from a database that includes a wide range of health related and epilepsy
related variables, as well as demographical data, neuropsychological data, data from a comprehensive
personality inventory and results from a QOL-questionnaire. Thus, the aim of this study was to analyze
predictors of QOL based on such a range of variables.
Methods: Adults with epilepsy on antiepileptic (AED) monotherapy and without epileptic seizures for at
least 2 years (n = 158) were assessed with the QOLIE-89.
Results: The main ﬁndings were that QOL in well-controlled epilepsy patients was in the normal range
and that presence of substantial health related concerns was a signiﬁcant predictor of poor QOL.
Discussion: The ﬁndings that substantial health concerns predict poor QOL may have clinical
implications, as seizure-free epilepsy is a relatively benign condition, and careful information and
counselling about this may alleviate health concerns and improve quality of life.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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It is well established that active epilepsy may have a negative
impact on quality of life (QOL). Important inﬂuences are whether
the epilepsy remains active, progresses or remits.1 In patients with
active epilepsy, symptoms of depression and seizure worry have
been found to be of particular importance with regard to QOL.2
However, for most patients, epilepsy is a relatively benign
condition and about 70% become seizure-free, either without
medication or following pharmacological treatment.3 Most studies
of QOL in seizure-free epilepsy patients suggest normal or near-
normal function with regard to general health proﬁle, social
activity, educational level, employment rate, neuropsychological
function and behavioral adjustment.4–7 Schachter8 argues that
QOL for patients with epilepsy is determined by more than seizure
control and he points to the important factors for QOL like mood
disorders, stigma, seizure worry, self-esteem and self-mastery. In
line with this some recent studies of seizure-free patients have
found impaired QOL. These studies report the reduction in overall
QOL, in social and physical function, in symptoms of depression,
health concerns and low self-esteem, in a higher proportion of* Corresponding author. Tel.: +47 92097373; fax: +47 22921783.
E-mail address: erik.hessen@nevropsykologi.no (E. Hessen).
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doi:10.1016/j.seizure.2009.04.008patients thanwould normally be expected.7,9,10 In one recent study
103 patients on monotherapy, seizure-free for at least 1 year,
completed questionnaires on demographic and clinical data, QOL
and subjective experience of antiepileptic (AED) drug side
effects.29 The study found that subjective experience of treatment
side effects and unemployment were the only signiﬁcant
predictors of poor overall QOL. The ﬁnding that side effects of
AEDmonotherapy predicts poor quality of life does not match well
with the results of a recently published study that found no
signiﬁcant improvement in QOL after AED-withdrawal in seizure
free patients on monotherapy.12 Neither do the results correspond
to the ﬁndings of another new study of behavioral consequences of
AED-withdrawal in seizure free patients, were only very slight
improvement in mood and irritability was found.30 On this
background, the possible relation of AED monotherapy and poor
QOL seems to be uncertain.
To our knowledge previous studies on QOL in well-controlled
epilepsy have not investigated determinants for QOL from a
database that includes a wide range of health related and epilepsy
relatedvariables, aswell asdemographical data, neuropsychological
data, data from a comprehensive personality inventory and results
fromaQOL-questionnaire. Thus, the aimof this studywas toanalyze
predictors of QOL based on such a range of variables. The Quality of
Life in Epilepsy-89 (QOLIE-89)11 is a common measure of QOL, and
the overall QOLIE-89 score was chosen as the outcome measure.vier Ltd. All rights reserved.
Table 1
Demographic and clinical characteristics of study patients.
Demographic and clinical variables All study
patients (n = 158)
Mean age (SD) 38 (11.8)
Female (%) 83 (53)
Education years (SD) 13.1 (2.7)
Work (%) 152 (96)
Retirement/disability beneﬁt (%) 6 (4)
Epilepsy onset 18 years (%) 58 (37)
Seizure free >5 years (%) 106 (67)
Duration of seizure freedom years (SD) 10.1(4.5)
Partial seizures (%) 115 (73)
Generalized seizures (%) 41 (26)
Presence of GTCS (%) 37 (23)
Known etiology (%) 45 (28)
MRI pathology (1 T) (%) 39 (25)
Carbamazepine (%) 96 (61)
Valproate (%) 35 (22)
Phenytoin (%) 14 (9)
Phenobarbital (%) 4 (3)
Lamotrigine (%) 7 (4)
Epileptiform activity on the EEG (%) 63 (40)
AED within therapeutic range (%) 121 (77)
Normal neurological status (%) 149 (94)
Neuropsychological impairment: 2 out of 13 T-scores 30 (%) 35 (22)
Subnormal QOLIE-89: T  39 (%) 14 (9)
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of life both in active and seizure-free epilepsy,we hypothesized that
symptoms of depression, signiﬁcant health concerns and unem-
ployment/disability beneﬁt would be the most important factors
affecting QOL in patients with well-controlled epilepsy.
2. Methods
2.1. Patients
The patients described in the present paper were participants in
a large study investigating the withdrawal of AEDs in seizure-free
epilepsy patients on monotherapy. They were selected on basis of
clinical criteria from the epilepsy registry at the Akershus
University Hospital and from six neurological outpatient clinics
in the Oslo area: they should have a diagnosis of epilepsy (at least
two unprovoked seizures), be between 18 and 67 years old and
seizure free on monotherapy for at least 2 years at the time of
inclusion. Excluded patients were with: juvenile myoclonus
epilepsy (JME), poly-pharmacy, paroxysmal epileptiform activity
in patients with primarily generalised epilepsy, mental retarda-
tion, two prior withdrawal attempts, pregnant or seeking
pregnancy, progressive neurological disease, other serious disease
which may inﬂuence the health status of the patient in the study
period and co-medication. Initially, 241 patients appeared to fulﬁl
the inclusion criteria andwere invited to participate in the study. A
total of 83 (34%) patients were not eligible, either based on
exclusion criteria or because they declined to participate. As many
as 32 (13%) patients declined to participate. This rather large
numbermust be viewed on the background that the studywas part
of a withdrawal study of AEDs, and many patients did not want to
participate due to fear of seizure relapse. The remaining 158
patients underwent a neurological exam, a neuropsychological
assessment and answered the QOLIE-89. A total of 126 (80%)
agreed to answer the Minnesota Multiphasic Personality Inven-
tory-2 (MMPI-2).13
2.2. Tests
A total of 13 neuropsychological tests, 2 subscales from the
MMPI-2 and the overall score from QOLIE-89 were employed:
1. Learning and memory: verbal learning and memory were
assessed with the Rey Auditory and Verbal Learning Test
(RAVLT).14,15 Visual memory was measured with visual
reproduction II from the Wechsler Memory Scale-Revised
(WMS-R).16
2. Attention and psychomotor speed: different aspects of visual
attention and psychomotor speed were measured with the Trail
Making Test A and B17 and Digit Vigilance Test.18
3. Aspects of executive functions: verbal ﬂuency was tested by the
COWA19 and response inhibition was measured by the Stroop
Neuropsychological Screening Test (SNST).20
4. Choice Reaction Time: aspects of these functions were assessed
with three subtests of the Norwegian Edition of California
Computerized Assessment Package.21
5. Motor coordination: motor speed and complex coordination was
measured by the Grooved Pegboard Test.22
6. Depression and health concerns: depression and health concerns
were assessed with two subscales (D and HEA) from the
Norwegian Edition of MMPI-2.13,23 Norwegian normative data
were used to score data from the MMPI-2.23 Deﬁnition of
abnormal function was T-scores equal to or greater than 65 on
the different subscales.
7. Quality of life: the Quality of Life in Epilepsy-89was developed in
the United States (QOLIE-89).11 Several content scores can bederived but the most common summary measure is the overall
QOLIE-89 score, which was chosen as the outcome measure in
this study. The reliability and validity of the Norwegian version
of the QOLIE-89 has been conﬁrmed in a study by Stavem et al.24
All the test results were converted to T-scores, a normally
distributed scale with a mean score of 50 and standard deviation
(SD) of 10.
2.3. Statistical analysis
Statistical analyses were performedwith the Statistical Package
for Social Sciences for Windows (SPSS, version 12.0). First,
descriptive statistics of the demographic, clinical and behavioral
characteristics of the patient population were computed. To assess
possible predictors of poor QOL we tested variables of importance
in a logistic univariate model. QOL was dichotomised, with the
categories normal (T  40) and subnormal (T  39) as the
dependent variable. The independent variables included MRI
pathology, known etiology, epileptiform activity on EEG, presence
of GTCS, presence of IGE, complex partial seizures, epilepsy onset
at age<18 years, duration of seizure freedom>5 years, AEDwithin
therapeutic range, AED above median serum level, pathological
neurological exam, neuropsychological impairment, unemploy-
ment/disability beneﬁt, pathological MMPI-2 Depression Scale (D)
(T  65) and pathological MMPI-2 Health Concerns (HEA) Scale
(T  65). Deﬁnition of impaired neuropsychological function was 2
or more out of 13 test results with T-scores equal to or below 30.31
Because only 14 events occurred, the number of variables in the
ﬁnal multivariate analysis was limited to three (HEA scale T  65,
unemployment/disability beneﬁt, D-scale T  65).
3. Results
3.1. Demographical and clinical data
Demographic data and clinical information of the 158 study
patients are presented in Table 1. There were no demographic
differences between the 158 patients that both underwent
neuropsychological assessment and answered the QOLIE-89, and
the 126 patients that answered the MMPI-2. Overall QOLIE-89
Table 2
Test results expressed as T-scores.
Neuropsychological tests Mean T-scores all study
patients (SD) n = 158
RAVLT-trial 1–5 50.3 (9.4)
RAVLT-delayed recall 47.1(10.4)
Visual reproduction II 51.9 (8.9)
Trail making test A 46.2 10.6)
Trail making test B 47.2(11.5)
Digit vigilance test-time 45.4(11.5)
COWA 42.1(10.1)
Stroop color-word 52.6 19.9)
Grooved Pegboard DH 49.1(12.2)
Grooved Pegboard NDH 46.5(10.3)
CalCAP n = 155
Choice RT-BASE 44.8(13.3)
Choice RT-LEX 43.2(11.6)
Choice RT-FORM 49.0(11.8)
MMPI-2 n = 126
Depression (D) 59.0 (12.3)
Health Concerns (HEA) 58.7 (12.6)
QOLIE-89 n = 158
Overall score 54.8 (9.0)
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also similar between these two groups, with the exception of
somewhat poorer scores among the 126 patients that answered
the MMPI-2 on two tests: Delayed Visual Memory: T = 49.0 versus
T = 53.0 (p = 0.016), and COWA (word ﬂuency): T = 38.5 versus
T = 43.0 (p = 0.020).
Neuropsychological function of the study patients has been
described previously.6 The group achieved their poorest perfor-
mance on the COWA (T = 42.1), the Choice Reaction Time Base
(T = 44.8) and Choice Reaction Time Lexical (T = 43.2) whereas the
remaining scores are close to T = 50 (Table 2). Impaired neurop-
sychological function, deﬁned as two or more T-scores30 (from a
total of 13 tests), was evident in 35 (22%) patients (Table 1).
An analysis of the behavioral function of the patient group has
recently been described by Hessen et al.7 Themean T-scores on the
subscales from the MMPI-2, hypothesized to predict poor QOL,
were close to one standard deviation above the normative mean:
Depression (D) (T = 59.0) and HEA (T = 58.7) (Table 2).
3.2. Quality of life
The mean group score on the QOLIE-89 was almost 5 T-scores
above the normative mean (T = 54.8) (Table 2). Subnormal QOLIE-Table 3
Predictors of QOL in well-controlled epilepsy patients.
Variable Univariate an
QOLIE-89 T-score 39 OR
MMPI-2 Health Concerns (HEA) T-score 65 16.92
Disability beneﬁt 9.61
MMPI-2 Depression (D) T-score 65 4.91
Complex partial seizure 2.22
Epilepsy onset 18 years 1.52
Idiopathic generalized epilepsy 1.31
Pathological neurological exam 1.26
AED above median serum level 1.24
Known etiology 1.12
MRI pathology 1.06
Duration of seizure freedom >5 years 1.06
Epileptiform activity on EEG 1.04
AED within therapeutic range 0.82
Neuropsychological impairment: 2 out of 13 T-scores 30 0.96
Presence of GTCS 0.2589 score deﬁned as T  39 was evident in 14 (9%) of the patients
(Table 1).
3.3. Prediction of quality of life
Univariate regression analysis revealed signiﬁcant association
between subnormal QOLIE-89 score and patients with substantial
health concerns, patients unemployed/on disability beneﬁt and
patients with depression (Table 3). However, multiple regression
analysis showed that a pathological score on the MMPI-2 Health
Concerns scale was the only signiﬁcant predictor of poor quality of
life (OR = 10.76, p = 0.007).
4. Discussion
Themain ﬁndings of the present studywere that (i) QOL inwell-
controlled epilepsy patients was in the normal range and that (ii)
presence of substantial health concerns and worries was a
signiﬁcant predictor of poor quality of life.
To our knowledge previous studies of QOL in well-controlled
epilepsy have not been able to investigate determinants for QOL
from a database that in addition to include a wide range of health
related and epilepsy related variables, as well as demographical
data, data from a comprehensive personality inventory also
included neuropsychological data.
There is reason to believe that the patients participating in this
study are representative of themajority ofwell-controlled epilepsy
patients.3,25 However, the ﬁndings are not valid for all seizure-free
epilepsy patients, as persons with poly-pharmacy,26 paroxysmal
epileptiform activity with primarily generalised epilepsy,27 mental
retardation, and progressive neurological disease were excluded
from the study.
The mean group score on the overall QOLIE-89 was 4.8 T-scores
higher than the normative mean reported in the US.11 The US
normative data are based on a sample of 304 persons from 25
epilepsy centers. Of these only 21 (7%) had been seizure free for the
last 12 months. Thus, in our sample of patients with less severe
epilepsy, seizure-free for 2 years or more, we would expect better
QOL and higher mean group scores.
Based on multivariate regression analysis, subnormal overall
QOLIE-89 score was only predicted by presence of abnormally
high score on the HEA scale from the MMPI-2. High scorers on
the HEA scale believe they are experiencing poor health, worry
about their health and often report a variety of neurological and
gastrointestinal symptoms.28 The ﬁnding that considerable
health concerns predicts poor QOL may compare well withalysis Multivariate analysis
p OR 95% CI p
0.000 10.76 1.93–60.02 0.007
0.006 6.37 0.49–82.31 0.16
0.016 1.89 0.44–8.19 0.39
0.24
0.48
0.69
0.83
0.75
0.85
0.45
0.91
0.65
0.67
0.95
0.19
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health concern – seizure worry – have been found to be of
particular importance.2 In the same study of active epilepsy,
Loring et al. found that depression also was an important
predictor of poor QOL. Univariate analysis in the present study
indicated an association of high depression score on the MMPI-2
and poor OQL. Another study of predictors of QOL in seizure-free
epilepsy patients29 found that unemployment was a signiﬁcant
predictor of poor overall QOL. Univariate analysis in the present
study also indicated an association of a similar variable –
unemployment/disability beneﬁt – and poor OQL. However,
mulitivariate regression revealed that none of these associations
were strong enough to be signiﬁcant.
The ﬁnding of the present study of mean group score on the
QOLIE-89 in the normal range compares well with results from
other studies of QOL in well-controlled epilepsy patients. In a large
study Jacoby4 found minimal dysfunction with regard to energy,
emotion, sleep, social isolation, physical mobility and stigmatisa-
tion, in patients seizure-free for at least 2 years. Additionally
employment rates were close to normal. In a Norwegian study
Stavem et al.5 compared the health status of people with epilepsy
with a general reference population. They found that 70% were
seizure free for 1 year or more and that these had QOL-scores (SF-
36) close to those of the general population. Hessen et al.6 found, in
a large group of adult patients, seizure free for at least 2 years on
AED monotherapy, that neuropsychological function was in the
normal range, and that education level and employment status
were as normally expected in Norway. In another study by Hessen
et al.7 of patients seizure-free formore than 2 years, group analysis
revealed that behavioral adjustment as measured with the
Minnesota Multiphasic Personality Inventory-2 (MMPI-2), was
in the normal range.
However, some recent studies support the ﬁndings of the
present study and indicate that aspects of QOL in some seizure-
free patients may be poorer than normally expected. In the
study by Hessen et al.,7 abnormally elevated scores on the
MMPI-2 were recorded on scales of depression, health-related
concerns, low self-esteem, negative treatment indicators, and
physical complaints, in a higher proportion of patients than
would normally be expected. Multiple regression analysis
showed that MRI pathology was a signiﬁcant predictor for
low self-esteem, and that epilepsy onset 18 years was a
signiﬁcant predictor of poor work capability. These ﬁndings may
be in line with the results from a study by Kobau et al.,10 where
persons without seizures the last 3 months reported impaired
quality of life. However, this result may be caused by the
narrower deﬁnition of seizure freedom than that employed in
other studies on seizure free patients. One smaller study9 seem
to support the two latter studies, in that they ﬁnd clear
reduction in social and physical function, when persons with
well-controlled epilepsy were compared to healthy controls.
Although QOL in well-controlled epilepsy predominantly is
comparable to the general population, the latter studies indicate
that aspects of QOL in seizure-free patients may be poorer than
normally expected.
The ﬁnding that the presence of substantial health concerns is a
signiﬁcant predictor of subnormal QOL in the common, seizure-
free, epilepsy patient may have clinical implications. Studies have
shown that for most patients that achieve seizure-freedom, either
without medication or following pharmacological treatment,
epilepsy is a relatively benign condition3 with only minimal
health problems.4,5 Second to treatment of the epilepsy, an
essential clinical aim is to improve the QOL of the patients. Based
on the knowledge that patients with substantial health concerns
are at risk of poor QOL, there ought to be a clear opportunity for
improvement of QOL in these patients, through careful informationand counselling about the relatively benign condition that well-
controlled epilepsy is.
In conclusion, the main ﬁndings of the present study were
that QOL in well-controlled epilepsy patients was in the normal
range and that presence of substantial health concerns and
worries was a signiﬁcant predictor of poor quality of life. The
ﬁndings may have clinical implications, as seizure-free epilepsy
is a relatively benign condition, and careful information and
counselling about this may alleviate health concerns and
improve quality of life.
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